Two-component vector-based vaccine Ad26.ZEBOV, MVA-BN-Filo against Ebola fever: A review of clinical studies

INTRODUCTION. High reactogenicity of the existing Ebola vaccines necessitates the development of safer and more efficacious alternatives. A solution is to use new recombinant vectorbased vaccines, such as Ad26.ZEBOV (a recombinant vaccine based on non-replicating human Ad26 serotype with an inserted...

ver descrição completa

Detalhes bibliográficos

Principais autores:	L. F. Stovba, O. V. Chukhralya, D. I. Paveliev, M. I. Soldatenkova, D. P. Belozerov, A. A. Petrov, S. V. Borisevich
Formato:	Artigo
Idioma:	Russo
Publicado em:	Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2026-04-01
coleção:	Биопрепараты: Профилактика, диагностика, лечение
Assuntos:	лихорадка эбола вирус эбола вакцина векторная вакцина двухкомпонентная вакцина вакцинация ревакцинация клинические исследования иммуногенность безопасность
Acesso em linha:	https://www.biopreparations.ru/jour/article/view/710
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!